Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC02349 (Long intergenic non-protein coding RNA 2349) is a non-coding RNA gene that produces an RNA transcript longer than 200 nucleotides, which does not overlap any protein-coding genes[1][3]. Genes of this class, known as lincRNAs, are distinguished by their intergenic position and lack of protein-coding potential[3][7]. LincRNAs, including LINC02349, are known to participate in the regulation of chromatin states, gene transcription, and genome architecture, and may influence cell phenotype and disease through these mechanisms, although the direct molecular and functional characterization of LINC02349 is currently lacking in the published literature[1][3][7]. LincRNAs are broadly implicated in gene expression fine-tuning and exhibit tissue specificity[3]. While lincRNAs have been associated with cancer and other pathologies, there is no direct evidence for LINC02349’s role in specific diseases or as a druggable target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2349 (LINC02349).